Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has appointed Dr. Jack Antel, a world-renowned multiple sclerosis (MS) expert and Professor of Neurology at McGill University, as clinical advisor to support the development of Lucid-21-302 (“Lucid-MS”), the company’s patented investigational drug designed to inhibit demyelination in MS. This announcement marks a significant step forward in the clinical advancement of Lucid-MS as Quantum prepares to initiate Phase 2 studies.
Dr. Antel brings extensive expertise to the program, having received the National Multiple Sclerosis Society and American Academy of Neurology’s Dystel Award and authored over 450 published articles. He will guide the design of efficacy trials, leveraging his deep understanding of MS pathology and clinical research. Dr. Antel joins Dr. Peter Stys, Professor of Neurosciences at the University of Calgary, who continues to serve as clinical advisor. This dual advisory strength underscores Quantum’s commitment to rigorous scientific development.
Lucid-MS is a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical models. Myelin degradation is the underlying mechanism of multiple sclerosis, a chronic neurodegenerative disease that affects millions worldwide. The appointment of Dr. Antel is expected to enhance the credibility and strategic direction of the program as Quantum moves toward clinical trials.
Quantum BioPharma is a biopharmaceutical company focused on building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is advancing Lucid-MS. Additionally, Quantum retains a 20.11% stake in Unbuzzd Wellness Inc., which markets the OTC product unbuzzd(TM), and receives royalty payments from its sales. The company also holds strategic investments via its subsidiary FSD Strategic Investments Inc.
For more details, the full press release is available at https://ibn.fm/NWMFj. Investors can find the latest news and updates on QNTM at the company’s newsroom: https://ibn.fm/QNTM.
